NATCO gets tentative US FDA approval for Ibrutinib tablets
NATCO feels that it is eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Imbruvica
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL
Data from Phase 3 E1912 study showed previously untreated patients aged 70 years or younger treated with ibrutinib plus rituximab…
AbbVie completes acquisition of Allergan
The transaction significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in…
J&J bumps up full-year profit view on strength of cancer drugs
The company is facing more than 13,000 lawsuits tied to anti-psychotic drug Risperdal as well as a range of lawsuits involving its…